The invention relates to a saponin derivative based on a saponin comprising a triterpene aglycone and a first saccharide chain and/or a second saccharide chain, and comprising: an aglycone core structure comprising an aldehyde group which has been derivatised; and/or the first saccharide chain wherein the first saccharide chain comprises a carboxyl group, which has been derivatised; and/or the second saccharide chain wherein the second saccharide chain comprises at least one acetoxy group which has been derivatised. The invention also relates to a first pharmaceutical composition comprising the saponin derivative of the invention. In addition, the invention relates to a pharmaceutical combination comprising the first pharmaceutical composition of the invention and a second pharmaceutical composition comprising any one or more of an antibody-toxin conjugate, a receptor-ligand-toxin conjugate, an antibody-drug conjugate, a receptor-ligand-drug conjugate, an antibody-oligonucleotide conjugate or a receptor-ligand-oligonucleotide conjugate. The invention also relates to the first pharmaceutical composition or the pharmaceutical combination of the invention, for use as a medicament, or use in the treatment or prophy laxis of a cancer, an infectious disease, viral infection, hypercholesterolemia, primary hyperoxalmia, haemophilia A. haemophilia B, alpha-1 antitrypsin related liver disease, acute hepatic porphyria, transthy retin-mediated amyloidosis, or an auto-immune disease. Furthermore, the invention relates to an in vitro or ex vivo method for trasferring a molecule from outside a cell to inside said cell, comprising contacting said cell with the molecule and with a saponin derivative of the invention.

The invention relates to a Quillaja saponaria saponin derivative based on a saponin comprising a triterpene aglycone and a first saccharide chain and/or a second saccharide chain, and comprising: an aglycone core structure comprising an aldehyde group which has been derivatised; and/or the first saccharide chain wherein the first saccharide chain comprises a carboxyl group, which has been derivatised; and/or the second saccharide chain wherein the second saccharide chain comprises at least one acetoxy group which has been derivatised. The invention also relates to a first pharmaceutical composition comprising the saponin derivative of the invention. In addition, the invention relates to a pharmaceutical combination comprising the first pharmaceutical composition of the invention and a second pharmaceutical composition comprising any one or more of an antibody-toxin conjugate, a receptor-ligand - toxin conjugate, an antibody-drug conjugate, a receptor-ligand - drug conjugate, an antibody-oligonucleotide conjugate or a receptor-ligand - oligonucleotide conjugate. The invention also relates to the first pharmaceutical composition or the pharmaceutical combination of the invention, for use as a medicament, or use in the treatment or prophylaxis of a cancer, an infectious disease, viral infection, hypercholesterolemia, primary hyperoxaluria, haemophilia A, haemophilia B, alpha-1 antitrypsin related liver disease, acute hepatic porphyria, transthyretin-mediated amyloidosis, or an autoimmune disease. Furthermore, the invention relates to an in vitro or ex vivo method for transferring a molecule from outside a cell to inside said cell, comprising contacting said cell with the molecule and with a saponin derivative of the invention.

A therapeutic composition including phenolic compounds derived from Opuntia littoralis (OL) includes an extract of Opuntia littoralis and lutein. The Opuntia littoralis extract can be formed by extracting an Opuntia littoralis plant powder with an alcohol to provide an Opuntia littoralis alcohol extract (OLAE) including the phenolic compounds. In an embodiment, the therapeutic composition can be effectively used as an analgesic for the treatment of pain, as an anti-inflammatory, as a treatment for immunological disorders, and/or as a treatment for oxidant conditions.

A therapeutic composition including phenolic compounds derived from Opuntia littoralis (OL) includes an extract of Opuntia littoralis and lutein. The Opuntia littoralis extract can be formed by extracting an Opuntia littoralis plant powder with an alcohol to provide an Opuntia littoralis alcohol extract (OLAE) including the phenolic compounds. In an embodiment, the therapeutic composition can be effectively used as an analgesic for the treatment of pain, as an anti-inflammatory, as a treatment for immunological disorders, and/or as a treatment for oxidant conditions.

The present invention relates to a method for obtaining single-use bioactive ingredients using a specific extraction process and new bioactive ingredients from renewable sources, in particular from the Amazon region, that can be used to prepare cosmetic compositions for treating skin, hair and/or scalp. Said bioactive ingredients are obtained by means of a subcritical-water extraction process parameterized to obtain bioactive compounds from different species and different plant components.

The present invention relates to a method for obtaining single-use bioactive ingredients using a specific extraction process and new bioactive ingredients from renewable sources, in particular from the Amazon region, that can be used to prepare cosmetic compositions for treating skin, hair and/or scalp. Said bioactive ingredients are obtained by means of a subcritical-water extraction process parameterized to obtain bioactive compounds from different species and different plant components.

The invention provides a composition including a succulent extract and an alginic acid component consisting of alginic acid and/or one or more salts thereof, wherein the succulent extract is present in an amount in a range from 0.1 wt % to 1000 wt % relative to the alginic acid component, both on a dry basis.

The invention provides a composition including a succulent extract and an alginic acid component consisting of alginic acid and/or one or more salts thereof, wherein the succulent extract is present in an amount in a range from 0.1 wt % to 1000 wt % relative to the alginic acid component, both on a dry basis.

Disclosed is a composition for ameliorating, preventing or treating an autoimmune skin disease, containing a super pink (Dianthus superbus L.) extract as an active ingredient.

Disclosed is a composition for ameliorating, preventing or treating an autoimmune skin disease, containing a super pink (Dianthus superbus L.) extract as an active ingredient.